All episodes

Ep. 79: Hidden Hazards: A Dive into Covert Cerebrovascular Disease

Ep. 79: Hidden Hazards: A Dive into Covert Cerebrovascular Disease

18m 22s

Moderator: Barbara Tettenborn (St. Gallen, Switzerland)

Guest: Thomas Meinel (Bern, Switzerland)

Thomas Meinel, a clinician scientist at the Burn Stroke Research Center in Switzerland, is hosted by Barbara Tettenborn as they discuss covert cerebrovascular disease. His research, particularly on strokes in patients on anticoagulation, is explored, highlighting the frequency and clinical implications of covert cerebrovascular lesions. Meinel emphasizes the current lack of clear evidence for managing these conditions. He also shares insights into ongoing studies that aim to connect epidemiological knowledge with clinical practices, encouraging neurologists to recognize and address covert cerebrovascular disease in patient care.

Ep. 78: Advocating for Brain Health

Ep. 78: Advocating for Brain Health

23m 57s

Moderator: Rolf Fronczek (Leiden, The Netherlands)

Guest: Matilde Leonardi (Milan, Italy)
Celebrate the end of the year with us with this special episode on Brain Health! Rolf Fronczek hosts Matilde Leonardi discussing her international neurology career and passion for Brain Health. She highlights the WHO Global Action Plan on epilepsy, stresses the increasing global burden of neurological diseases, and advocates for preventative measures. Leonardi details EAN's Brain Health Strategy, urging neurologists to advocate for brain health individually and nationally. Emphasizing a bio-psychosocial approach, she invites participation in EAN's leadership and advocacy training to contribute to shaping global brain health.

Ep. 77: 30th Anniversary of the European Journal of Neurology

Ep. 77: 30th Anniversary of the European Journal of Neurology

17m 54s

Moderator: Barbara Tettenborn (St. Gallen, Switzerland)

Guest: Didier Leys (Lille, France)

In this eanCast episode, Barbara Tettenborn interviews Didier Leys, Editor-in-Chief of the European Journal of Neurology, marking its 30th anniversary. Leys discusses the journal's evolution, challenges, and current impact factor of five. He outlines his daily editorial duties, stressing manuscript selection, ethical standards, and team management. Future plans include webinars, a history special issue, a virtual issue of top-cited articles, and video interviews with editors. He also encourages young researchers to submit, citing impact factor and submission delay importance. The episode closes with a glimpse into exciting 30th-anniversary initiatives.

Ep. 76: Neurological side effects and drug interactions of new antiviral drugs against SARS-CoV-2

Ep. 76: Neurological side effects and drug interactions of new antiviral drugs against SARS-CoV-2

15m 56s

Moderator: Johann Sellner (Mistelbach, Austria)

Guest: Tamuna Akhvlediani (Tbilisi, Georgia)

In this podcast episode, Prof. Johann Sellner interviews Prof. Tamuna Akhvlediani about the neurological aspects of new antiviral drugs for SARS-CoV-2. They discuss drugs like monoclonal antibodies, paxlovid, and remdesivir, emphasizing their mechanisms and potential applications beyond COVID-19. Prof. Akhvlediani details neurological side effects observed in trials and significant drug interactions, especially in chronic neurological patients. The episode closes with insights into managing these interactions in clinical practice.

Ep. 75: Nosocomial Infections of the central nervous system

Ep. 75: Nosocomial Infections of the central nervous system

14m 13s

Moderator: Johann Sellner (Mistelbach, Austria)

Guest: Tamuna Akhvlediani (Tbilisi, Georgia)

In this last episode on Infectious Diseases, Prof. Johann Sellner and Prof. Tamuna Akhvlediani explore nosocomial infections of the central nervous system (CNS). They cover the definition, common pathogens, and prevention methods like infection control and standardized surgery. Prof. Akhvlediani specifies prevalent CNS infections and addresses challenges in prevention and treatment, notably due to antimicrobial resistance. The conversation concludes with insights into treatment strategies, emphasizing the increasing challenge of antimicrobial resistance in healthcare-associated infections.

Ep. 74: EBV in the pathogenesis of multiple sclerosis

Ep. 74: EBV in the pathogenesis of multiple sclerosis

14m 29s

Moderator: Tamuna Akhvlediani (Tbilisi, Georgia)

Guest: Johann Sellner (Mistelbach, Austria)

In this week’s podcast hosted by Dr. Tamuna Akhvlediani, Prof. Johann Sellner discusses the connection between Epstein-Barr virus (EBV) and multiple sclerosis (MS). They explore the immune-mediated nature of MS, focusing on the impact of EBV and recent studies linking its infection to MS development. The episode delves into the controversies, hypotheses, and potential therapies related to EBV and MS, concluding with information on ongoing clinical trials and the influence of existing MS treatments on EBV.

Ep. 73: Neuroinfections in times of COVID-19

Ep. 73: Neuroinfections in times of COVID-19

17m 52s

Moderator: Tamuna Akhvlediani (Tbilisi, Georgia)

Guest: Johann Sellner (Mistelbach, Austria)

Dr. Tamuna Akhvlediani hosts Professor Johann Sellner in a podcast discussing the impact of COVID-19 on neuro infections. Professor Sellner covers global neuro infections, the decline during lockdowns, and the effectiveness of measures like face masks and vaccination. The episode emphasizes lessons learned, including insights into chronic neuro infection care disruptions and challenges, such as neuro-AIDS management during the pandemic. It concludes with findings from a study on how COVID-19 affected different neurological subspecialties.

Ep. 72: Outcome of neurological toxicities of immune checkpoint inhibitors and the effect of drug rechallenge

Ep. 72: Outcome of neurological toxicities of immune checkpoint inhibitors and the effect of drug rechallenge

14m 55s

Moderator: Yildiz Değirmenci (Istanbul, Turkey)

Guest: Antonio Farina (Florence, Italy)

This week, Dr. Yildiz Değirmenci and Dr. Antonio Farina discuss life-threatening neurological toxicities from immune checkpoint inhibitors. Dr. Farina highlights high fatality rates, long-term disabilities, and the urgency of early recognition and treatment. The episode explores management, including discontinuation and corticosteroids, and factors influencing outcomes. It touches on the association between adverse events and treatment response, resuming inhibitors, and stresses a multidisciplinary approach for informed decision-making. The conclusion emphasizes the importance of neurologists' awareness in addressing these rare yet significant neurological complications.

Ep. 71: Neurological complications from cancer immunotherapy

Ep. 71: Neurological complications from cancer immunotherapy

18m 51s

Moderator: Antonio Malvaso

Guest: Stefania Cuzzubbo

Dr. Antonio Malva hosts Dr. Stefania Cuzzubbo to discuss neurological complications from cancer immunotherapy. Dr. Cuzzubbo highlights immune-related adverse events, focusing on peripheral nervous system issues. The importance of early diagnosis using MRI, lumbar puncture, and nerve studies is emphasized. Treatment involves promptly stopping the drug and using steroids, with alternative therapies explored for steroid-refractory cases. Continued research in this evolving field is crucial.

Ep. 70: Paraneoplastic neurological syndromes: diagnosis and treatment

Ep. 70: Paraneoplastic neurological syndromes: diagnosis and treatment

17m 51s

Moderator: Antonio Malvaso (Pavia, Italy)
Guest: Alberto Vogrig (Udine, Italy)
In this episode of EAN Cast Weekly Neurology, Dr. Antonio Malvaso, a neurology resident, welcomes Dr. Alberto Vogrig, an international expert in the field of paraneoplastic neurological syndromes. They discuss the definition of these syndromes, emphasizing the causal relationship with cancer and their immune-mediated pathogenesis. They also talk about the revised diagnostic criteria and the importance of clinical diagnosis, laboratory techniques, and oncologic screening. The treatment for these syndromes includes immunosuppression, cancer therapy, and symptomatic treatment, tailored to the specific symptoms.